News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Valeant Pharmaceuticals International (VRX) To Acquire Xcel Pharmaceuticals, Inc.; Acquisition Expands Valeant's Neurology Franchise In North America; Adds Retigabine To Pipeline


10/19/2005 5:12:36 PM

COSTA MESA, Calif.--(BUSINESS WIRE)--Feb. 2, 2005--Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has signed a definitive agreement to acquire Xcel Pharmaceuticals, a privately held specialty pharmaceutical company focused on neurology products in the United States. The transaction significantly expands Valeant's business in North America and enhances the company's neurology franchise through the acquisition of key products and a highly specialized neurology sales organization consisting of 94 professionals. The transaction also adds retigabine, a novel Phase 3 candidate in clinical development for the treatment of epilepsy, to Valeant's pipeline. Valeant plans to market retigabine in the United States and key foreign markets once the Phase 3 trials are completed, subject to regulatory approval.

Read at AP
Read at BioSpace.com

comments powered by Disqus
AP
BioSpace.com
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES